Innovative Multispecific Nanobody Targeting DRD2 and PDCD1 for Advanced Lung Cancer Therapy

VHH-P840 is a cutting-edge, humanized nanobody construct specifically engineered to target dopamine receptor D2 (DRD2) and programmed cell death 1 (PDCD1). Currently in the Biological Testing stage, VHH-P840 is designed to address the demanding therapeutic needs in lung cancer treatment. By precisely engaging DRD2 and PDCD1, this multispecific antibody has the potential to modulate both tumor growth and immune evasion mechanisms, paving the way for novel intervention strategies in lung cancer therapy.

Licensing Opportunity

VHH-P840 is available for out-licensing opportunities. We invite partnership discussions with organizations interested in advancing this innovative multispecific nanobody program for lung cancer and related indications.

Development Phase

Modality

VHH-P840 leverages a multispecific nanobody format, comprising tandemly fused single-domain antibodies that individually bind DRD2, PDCD1, and antigens on immune cells. These are linked to an Fc domain via specialized linkers and are expressed in Chinese hamster ovary cells. The single-domain antibody structure of nanobodies confers substantial benefits, including compact molecular size for enhanced tissue penetration and outstanding stability. These features are particularly advantageous in the context of lung cancer, as they facilitate improved tumor infiltration and resilience in challenging microenvironments, allowing for more effective targeting of heterogeneous cancer cells and the tumor-immune interface.

Target

The dual targets of VHH-P840 are DRD2 and PDCD1. DRD2 is a G protein-coupled receptor involved in multiple neurological and oncogenic processes, while PDCD1 plays a crucial role as an immune checkpoint regulator suppressing T-cell responses. DRD2 is expressed in both neural and certain peripheral tissues, including various tumor cells, whereas PDCD1 is predominantly found on activated T cells. Both DRD2 and PDCD1 are implicated in lung cancer pathogenesis; DRD2 modulates tumor growth and signaling pathways, while PDCD1 mediates immune escape. Targeting both DRD2 and PDCD1 is strategically valuable, as it enables VHH-P840 to simultaneously impact tumor progression and restore antitumor immunity, establishing it as a highly differentiated asset for lung cancer intervention.

Mechanism of Action

VHH-P840 operates by simultaneously antagonizing DRD2-mediated signal transduction and inhibiting PDCD1 activity as an immune checkpoint. Its anti-DRD2 activity modulates tumoral signaling cascades that are pivotal for tumor cell proliferation and survival. Concurrently, the anti-PDCD1 function serves as an immune checkpoint inhibitor, revitalizing T-cell mediated cytotoxicity against cancer cells. Through its multispecific design, VHH-P840 offers the potential for comprehensive modulation of both tumor-intrinsic and immune-mediated pathways. The nanobody scaffold also provides versatility for developing future modalities, such as antibody-drug conjugates or bispecific constructs, broadening its translational impact in oncology.

Lung Cancer

Lung cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, characterized by high heterogeneity and complex tumor microenvironments. Current standards of care include surgery, chemotherapy, radiotherapy, targeted molecular therapies, and immune checkpoint inhibitors. Despite advances, prognosis for advanced lung cancer is poor, with many patients developing resistance to existing treatments or suffering from toxicities. A clear unmet medical need persists for novel therapeutics that offer durable responses and improved safety profiles. VHH-P840 represents a promising candidate by targeting both oncogenic signaling via DRD2 and immune evasion through PDCD1, aiming to overcome resistance mechanisms and promote lasting antitumor effects. Its innovative modality holds the potential to significantly impact patient outcomes and address critical gaps in lung cancer therapy.